PPARδ, a Potential Therapeutic Target for Heart Disease

Qinglin Yang\textsuperscript{1} and Qinqiang Long\textsuperscript{2}

\textsuperscript{1}Cardiovascular Center of Excellence, LSU Health Science Center, 533 Bolivar St, New Orleans, LA 70112, USA

\textsuperscript{2}Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China

Abstract

The nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ) can transcriptionally regulate target genes. PPARδ exerts essential regulatory functions in the heart, which requires constant energy supply. PPARδ plays a key role in energy metabolism, controlling not only fatty acid (FA) and glucose oxidation, but also redox homeostasis, mitochondrial biogenesis, inflammation, and cardiomyocyte proliferation. PPARδ signaling is impaired in the heart under various pathological conditions, such as pathological cardiac hypertrophy, myocardial ischemia/reperfusion, doxorubicin cardiotoxicity and diabetic cardiomyopathy. PPARδ deficiency in the heart leads to cardiac dysfunction, myocardial lipid accumulation, cardiac hypertrophy/remodeling and heart failure. This article provides an up-to-date overview of this research area and discusses the role of PPARδ in the heart in light of the complex mechanisms of its transcriptional regulation and its potential as a translatable therapeutic target for the treatment of cardiac disorders.

1. Introduction

Peroxisome proliferator-activated receptors (PPAR\textsubscript{α}, -γ and -δ) belong to a nuclear receptor transcription factor superfamily that regulates metabolic transcription. Ligands of PPAR\textsubscript{α} and -γ are clinically effective in treating dyslipidemia and insulin resistance, although adverse risks have remained a concern (see review \cite{1}). PPARδ (NR1C2, encoded by the Ppard gene, also known as PPARβ) was first cloned in the early 90’s of the 20th century \cite{2,3}. No FDA approved drug targeting PPARδ is available so far notwithstanding early-stage clinical trials on the use of PPARδ agonists (e.g., KD-3010 and MBX-8025) to treat atherosclerosis, metabolic disorders and liver injury \cite{4–6}. Early-stage clinical trials of selective PPARδ agonists Seladelpar (MBX-8025) in patients with primary biliary cholangitis was terminated due to grade 3 increases in serum transaminase levels \cite{7}. Therefore, a PPARδ-specific therapeutic strategy remains in perspective with improved selectivity and minimal off-target effects.
As the most energy demanding organ, energy metabolism is essential for the normal function of hearts. A normal adult heart predominantly relies on the energy from fatty acid oxidation (FAO). PPARs play essential roles in transcriptional regulation of many aspects of cellular metabolism, especially FAO. All three PPAR subtypes are expressed in heart cells (cardiomyocytes) [8–11]. PPARα controls the transcriptional expression of key enzymes that are involved in FA uptake and oxidation, triglyceride synthesis, mitochondrial respiration uncoupling and glucose metabolism [10, 12, 13]. The role of PPARγ in the heart has not been extensively studied due to its relatively low abundance. However, several studies on cardiomyocyte-restricted PPARγ mice demonstrate its crucial role in cardiac physiology, probably via its role in transcriptionally regulating myocardial FA metabolism and anti-oxidant defense [14–17]. The cardiac function of PPARδ was explored until subtype-specific synthetic ligands for PPARδ became available in the early 2000’s. In the heart, PPARδ is prominently expressed in cardiomyocytes and activation of PPARδ upregulates FAO transcripts as in cultured cardiomyocytes [18, 19]. Global PPARδ KO in mice is embryonically lethal due to placenta defects [20]. Survival PPARδ KO mice show an extremely lean phenotype [20]. Considering that potential compensation may conceal potential phenotypic manifestation, conditional PPARδ KO mouse lines were developed [20–29]. Inborn cardiomyocyte-restricted PPARδ deletion leads to cardiomyopathy and heart failure with impaired myocardial FAO [30]. Therefore, it becomes clear that all PPAR subtypes play roles in transcriptional regulation of myocardial energy and lipid homeostasis, but with differences in their cardiac expression levels and yet to be defined differential regulation on various aspects of energy metabolism. Further studies on the potential distinctive roles of each PPAR subtype in the heart should provide new therapeutic targets for treating heart disease. In this review, we focus on summarizing the biological function and clinical implications of PPARδ in the heart.

2. PPARδ Plays a Crucial Role in Cardiac Pathophysiology

The optimal coupling of metabolism and function is essential for the normal structure/function of the heart. Cardiac metabolism is a key player in the development of cardiac pathophysiology as FAO provides a majority of energy for a normal heart to properly function [31, 32]. Metabolic adaptation becomes essential to meet the energy needs of the pathological heart ensue with various stimuli, such as mechanical overload, ischemia/reperfusion, aging, diabetes and drug cytotoxicity. Others and our studies documented that PPARδ is a key transcription factor that regulates almost all steps of metabolism (see review [9, 33], hence PPARδ can play a crucial role in determining cardiac pathophysiology.

Under various cardiac hypertrophy conditions, most studies show cardiac PPARδ is decreased [34, 35] as those of PPARα [12, 13]. PPARδ is reduced in hypertrophic cardiomyocytes induced by angiotensin II [34] and hypertrophic hearts resulted from transverse aortic constriction (TAC)-induced left ventricular pressure overload [35]. The impaired cardiac PPARδ expression could be reversed by anti-hypertrophic treatment [34, 36]. Studies using Western blots also showed protein contents of cardiac PPARδ are downregulated in doxorubicin-cardiac cytotoxicity [37] and STZ-induced diabetic hearts [38]. In contrast to the above investigations, another study using Western blot showed that cardiac PPARδ is upregulated in the heart with infarction in rats [39]. The reason for these
different findings of PPARδ in pathological hearts could be related to the specific pathological condition, the animal species/strain, and the technical issues of antibody specificity.

While changes of PPARδ expression in the pathological heart need further validation, the essential role of cardiac PPARδ is well established. Cardiomyocyte-restricted PPARδ deletion was achieved by breeding the floxed mice with a mouse line with cardiomyocyte-restricted expression of Cre recombinase (α-Myosin heavy chain-Cre). Inborn cardiomyocyte-restricted PPARδ deletion impairs myocardial FAO and leads to cardiomyopathy and heart failure [30]. To further gain insights into the function of PPARδ in the adult heart, we generated mice with Tamoxifen-induced cardiomyocyte-restricted PPARδ deletion by crossing the floxed PPARδ mice with a mouse line carrying α-Myosin heavy chain-Mer-Cre-mer. Adult mice with cardiomyocyte-restricted PPARδ deletion consistently show cardiac dysfunction, cardiac hyper-trophy and remodeling [40]. On the other hand, studies using gain-of-function approaches also mostly support a protective effect of PPARδ in the heart. Transgenic mice with cardiomyocyte-restricted expression of a constitutively active form of PPARδ show no overt cardiac phenotype, yet these mice become resistant to pressure overload-induced cardiac dysfunction [41].

Since the role and activity of PPARδ is not entirely dependent on its transcript or protein abundance but also on the molecular regulation that PPARδ exerts as gene inducer or repressor, studying the effects of pharmacological activators is therefore complementary to abundance studies. PPARδ selective ligands reduce hypertrophic response induced by phenylephrine in cultured rat neonatal cardiomyocytes and rat embryonic myocytes (H9C2) [42]. PPARδ activation improves angiotensin II-induced cardiac hypertrophy in vitro [43]. However, a later study on cultured rat adult cardiomyocytes shows upregulation of PPARδ activity and FAO gene expression with minimal effect on cell growth [43]. It remains unclear whether the discrepancy is related to the differentiation states of cardiomyocytes or the culture conditions used in the studies. In vivo pharmacological studies in the literature provide further support. An early study on rats shows the PPARδ agonist GW0742 protects against right heart hypertrophy from post-myocardial infarction [44]. Pharmacological studies show that baicalin and Moringa oleifera Seeds, both extracted from plants, protect the heart from TAC-induced pressure overload or hypertension from the development of hypertrophy via enhancing cardiac PPARδ expression [35, 45]. The cardiac protective effect of PPARδ is further supported by studies in animal models with myocardial ischemia/reperfusion (IR) injury. Activation of PPARδ attenuates myocardial IR injury in rats [39] and mice [46]. Our results from a study on mice with cardiomyocyte-restricted transgenic expression of the constitutively active PPARδ supports the protective role of PPARδ activation. Mice with PPARδ activation showed improved cardiac function, reduced infarct size, and fibrotic remodeling [47]. Treatment with GW0742 protects the heart in a PPARδ-dependent manner [47]. It is interesting that another study on the effect of permanent myocardial infarct in rats shows functional effects of PPARδ agonist (GW0742) treatment, but with augmented cardiac fibrosis with no functional consequence [48]. However, a control group to determine the basal effect of PPARδ agonist (GW0742) was not included in this study, missing the opportunity to determine if GW0742 treatment alone could induce cardiac fibrosis. It is noted that the study assigned hearts to different groups based on the degree of
infarction determined by echocardiographic images were used for all experimental procedures. The overtly biased experimental design may oblivion correct interpretation of the outcomes. Further studies with careful experimental design should help clarify the conclusions.

The cardiac protective role of PPARδ activation has been validated further in other advert states. Cardiac cytotoxicity is a main clinical dilemma in the use of effective anti-cancer drugs. Evidence has emerged that activation of PPARδ protects against doxorubicin-induced cardiotoxicity. A PPARδ activator, L-165041, inhibits senescence in neonatal rat cardiomyocytes and H9C2 cells via interacting with Bcl6 to reduce apoptosis [49]. On the other hand, PPARδ ligand GW0742 exerts a protective role in neonatal rat cardiomyocyte treated with Doxorubicin by sustaining intracellular calcium concentration [50]. Baicalein, a natural PPARδ ligand, protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation [51].

Diabetes (type 1 and type 2) and obesity have a strong link to cardiac dysfunction, cardiac hypertrophy and heart failure (see review [52–54]). Normalizing cardiac PPARδ protein improves cardiac fibrosis in rats with streptozocin (STZ)-induced diabetes [37]. Induction of cardiac angiopoietin Like 4 (Angptl4) via PPARδ activation in the heart is essential in protecting against FA-induced oxidative stress [55], a key mechanism behind diabetic cardiomyopathy. Several reports indicate that restoring PPARδ protein expression in diabetic hearts from rats induced by STZ by various pharmacological compounds, such as histone deacetylase (HDAC) inhibitor [56], ginseng [9, 57] and ramipril [58]. However, many of these preliminary findings need further validation. Further studies are required to assess the PPARδ expression in the heart in transcript level, target gene expression and subtype-specific activity to confirm the observations.

In summary, It is apparent that most of the current studies illustrate that cardiac PPARδ may be repressed in cardiac disorders and PPARδ re-activation in the heart is protective (Figure 1), whereas PPARα re-activation in the heart could be detrimental [59, 60] or beneficial [61–64], possibly depending on the degree of activation.

3. Molecular and Biochemical Mechanisms Underlying the Biological Action of PPARδ in the Heart

3.1. PPARδ is a key transcriptional regulator of FA utilization in the heart

As a ligand-activated nuclear receptor and transcription factor, PPARδ regulates transcription in many tissues (see review [9, 65, 66]). Being ubiquitously expressed in the body, PPARδ is expressed preferentially in cardiomyocytes among other cell types in the heart [19]. In rat neonatal cardiomyocytes (RNCM), PPARδ regulates transcript expression of key genes involved in FA metabolism [19]. PPARδ-selective ligand and PPARδ overexpression in cultured RNCM promotes FA metabolic gene expression and the rate of FAO in a classic ligand binding dependent mechanism [19]. We and other further confirmed that PPARδ regulates the transcriptome of FA utilization in the heart (see reviews [9, 67, 68]). PPARδ is a key determinant of FA uptake in cardiomyocytes by upregulating FA
uptake genes, such as FA transport protein (FATP) and FA binding protein (FABP) [18, 19, 30, 40, 41, 69, 70]. Moreover, PPARδ ligand treatment not only upregulates key mitochondria-specific β-oxidation genes, such as Long-chain acyl-CoA synthetase (LACS), carnitine palmitoyltransferase very-long-chain acyl-CoA dehydrogenase (VLCAD), mitochondrial 3-ketoacyl-CoA thiolase, CPT-A, uncoupling protein 2 (UCP2), UCP3, pyruvate dehydrogenase kinase 4 (PDK4), medium chain acyl-CoA dehydrogenase (MCAD), long chain acyl-CoA dehydrogenase (LCAD) and malonyl-CoA decarboxylase (MCD), but also peroxisome-specific β-oxidation genes, such as acyl-CoA (ACO), and peroxisomal 3-ketoacyl-CoA thiolase [18, 19, 30, 40, 41, 69]. Further studies on cardiac-specific PPARδ mice provide definitive evidence supporting the role of PPARδ in maintaining constitutive FA metabolism in the heart [19]. In addition to depressed FAO, cardiomyocyte-restricted PPARδ knockout mice develop severe phenotypic changes, such as cardiac dysfunction, myocardial lipid accumulation and progressive heart failure. The dominant expression of PPARδ in cardiomyocytes of the heart explains at least in part the reason for mice with cardiomyocyte-restricted PPARδ knockout exhibit a devastating pathological consequence [19, 30]. Thus PPARδ may play a crucial role in metabolic homeostasis in the heart by maintaining intracellular FA content and a high-level FA metabolism observed in normal adult hearts.

Crosstalk or compensatory expression between PPARδ and the other PPAR isoforms has been identified in the heart [69]. Nonetheless, pharmacological or genetically PPARδ overexpression or activation did not modify the expression of PPARα and PPARγ in the heart in both physiological and pathological states [41, 69]. PPARα and PPARδ both regulate FA utilization in cardiomyocytes in an interdependent manner. Deletion of either of them from cardiomyocytes does not affect other PPARs’ effects on activating FA utilization gene expression [19, 30]. Interestingly, cardiomyocyte-restricted PPARδ knockout, but not the conventional PPARα knockout mice, exhibit neutral lipid accumulation in myocardium at basal state [19, 71], probably due to the mismatch of PPARδ activated FAO and lipid uptake. Until further investigation on a cardiomyocyte-restricted PPARα KO mouse line, it is impossible to draw a definitive conclusion on the differentiated roles of these two important transcription factors in the heart. Interestingly, a study on a mouse line with cardiac-specific overexpression of a wild-type PPARδ results in increased cardiac glucose uptake and oxidation in concomitant upregulation of glucose transporter type 4 (GLUT4) and phosphofructokinase (PFK) genes [46]. However, it remains unknown if these two genes are direct targets of PPARδ. A recent study demonstrates that PPARδ improves exercise endurance by reducing glucose and increasing fat metabolism in skeletal muscle [26]. Therefore, it is possible that the effects of PPARδ on cardiac glucose metabolism may be indirect. Further studies will be warranted to clarify the direct effect of PPARδ on myocardial glucose metabolism.

3.2. PPARδ regulates mitochondrial antioxidant defense

The normal function and structure of the heart rely heavily on the efficiency of energy supply, which is dependent on the redox homeostasis of mitochondria, the power plant of cells. Mitochondrial redox dysfunction will result in energy deficiency and excessive production of reactive oxygen species (ROS) in cardiomyocytes, impairing cardiac function.
and structure. Therefore, a better understanding of the mitochondrial redox regulation in the heart may yield novel therapeutic strategies for treating cardiac disorders.

In adult mouse hearts with induced PPARδ knockout, both mitochondrial biogenesis and cardiac antioxidant defense are impaired [40]. Specifically, PPARδ knockout from adult heart leads to oxidative damages with an impaired cardiac expression of superoxide dismutase 1 (SOD1) and SOD2 [40]. PPARα null mice with additional PPARδ knockout from the heart showed similar results [69]. Both the transcript and protein expression of SOD1 and SOD2 was repressed in PPARδ, but not PPARα deficient hearts [69]. No endogenous antioxidants are affected at the basal condition in the PPARα KO heart, supporting a notion that differential regulation of antioxidant expression in the heart may be the key factor contributing to the phenotypic changes in PPARδ deficient hearts. The effects of PPARδ activation in regulating antioxidant defense in the heart have also been validated in mouse models with cardiomyocyte-restricted overexpression of a constitutively active PPARδ. With an enhanced antioxidant defense, the PPARδ activating mice showed less oxidative injuries in the heart and stronger cardiac performance even under a left ventricular pressure overload condition [41]. Another study showed that activation of PPARδ protects cardiomyocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases [72]. The impaired expression of antioxidants should contribute to the cardiac dysfunction in the PPARδ deficient heart [30] and activation of PPARδ protects the heart at least partly via upregulating antioxidant levels in the heart under pressure overload condition [40, 41]. Other than the direct transcriptional regulation, the effect of PPARδ in myocardial lipid metabolism and glucose utilization [46] at various metabolic states in different pathological development stages may contribute to the antioxidant defense and myocardial protection of PPARδ ligand treatment and transgenic PPARδ overexpression [40, 73].

Taken together, the above investigations support mostly a protective role of PPARδ in regulating transcriptional expression of multiple endogenous anti-oxidants, protecting the heart under both physiological and pathological conditions.

### 3.3. PPARδ exerts anti-inflammation effects on the heart

Chronic inflammation is involved in the pathological development of myocardial ischemia/reperfusion injury [74, 75], pathological cardiac hypertrophy and congestive heart failure [76, 77]. Although remaining invalidated in patients, anti-inflammation to specific inflammation pathways remains a potential therapeutic target for the treatment of cardiac injuries and heart failure [78, 79].

The anti-inflammatory role of PPARα and PPARγ [80–82], later PPARδ [83], has been documented in the last decade. The anti-inflammatory effects of PPARs in the cardiovascular system have been extensively investigated, especially in their anti-inflammatory effects on macrophage foam-cell formation and atherosclerosis [84, 85]. PPARδ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells [86]. PPARδ represses transforming necrosis factor-α (TNF-α) in cultured cardiomyocytes via regulating the nuclear factor-κB (NF-κB) signaling pathway. We showed that a PPARδ-selective ligand, GW0742, inhibits the lipopolysaccharide (LPS)-induced TNF-α production in
cultured cardiomyocytes [87]. All these investigations strongly support that PPARδ exerts significant anti-inflammatory effects in the heart.

Several studies established a consistent mechanism for the anti-inflammatory effects of PPARδ by its direct or indirect interaction with NF-κB signaling [42]. An early study has shown that unliganded PPARδ sequesters the transcriptional repressor protein B cell lymphoma-6 (Bcl6) and prevents it from binding to the response elements in the promoter regions of its target genes [88]. Bcl6 is released from PPARδ and inhibits inflammatory signals [88–90]. PPARδ can interact with other transcription factors such as the p65 subunit of NF-κB, preventing NF-κB dependent transcription [42]. Furthermore, the roles of PPARδ in curbing palmitate-induced endoplasmic reticulum stress and inducing autophagy [91] may also contribute to its anti-inflammatory effects in cardiomyocytes.

Despite the well-recognized anti-inflammatory effects of PPARδ in the heart, further studies are required to translate these findings into clinical treatment of heart disease. The main issue is still related to the potential side effects of the existed PPARδ-selective ligands. On the other hand, the continuous discovery of naturally occurring ligands that could at least partially activating PPARδ may help identify compounds that have less side effect yet process PPARδ activation effects to achieve the therapeutic goal.

### 3.4. Potential adverse effects of PPARδ in the heart

Although most investigations support the beneficial effects of PPARδ on the heart, potentially detrimental effects of PPARδ have been reported. In cultured H9C2 cells, a cell line of myoblasts from rat embryonic hearts with few features of cardiomyocytes, pharmacological blocking of PPARδ signaling mitigates the cytotoxicity of docosahexaenoic acid (DHA), a key compound found in fish oil [92]. However, further in vivo studies are essential to validate this in vitro finding. Another study shows that PPARδ ligands (GW0742 or GW501516) treatment in mice leads to rapid development of cardiac hypertrophy and angiogenesis, presumably via direct activation of calcineurin [93]. However, we did not see any cardiac hypertrophic effects of GW0742 with the same dose and subcutaneous injection. The reason for the discrepant cardiac effects of systemic treatment of GW0742 is not clear, although we cannot rule out a transient reversible cardiac growth induced by the treatment with GW0742 in our study [94]. The same group went on to demonstrate that mice with induced vascular-specific overexpression of PPARδ show rapid cardiac hypertrophy [95]. Furthermore, the vascular overexpression of PPARδ does not protect against chronic ischemic injury of the heart [95]. However, this study does not clarify if systemic treatment of GW0742 triggers cardiac hypertrophy by its effects on the vasculature. Therefore, further studies on the PPARδ effects by assessing different cell types in the heart is needed in evaluating the potential clinical use of PPARδ ligands for the treatment of heart diseases.

In summary, the importance of PPARδ in cardiac pathophysiology is multi-faceted through direct transcriptional activation and secondary modulation of other transcriptional and cellular signaling pathways. For example, the PPARδ interaction with NF-kB attributes to its anti-inflammatory effects. It is also likely that the transcriptional effects of PPARδ on FA utilization, mitochondrial biogenesis and antioxidant defense are further integrating with other biological effects such as inflammatory processes and cell proliferation (Figure 2). We
recently uncovered that PPARδ activation facilitates the cell cycle re-entry of adult cardiomyocyte [94]. Since adult cardiomyocytes are mostly terminally differentiated, enabling terminally differentiated cardiomyocyte re-entering cell cycle remains a major challenge [96–98]. Our drug screen identified carbacyclin, a PPARδ activator, which induces cardiomyocyte proliferation via a PPARδ/PDK1/p38/Akt/GSK3β/β-catenin-pathway. Activating PPARδ signaling after myocardial infarction (MI) induces cardiomyocyte cell cycle activity and improves scarring as well as cardiac function [94]. PPARδ deletion from the heart reduces the effect of PPARδ-selective agonist, GW0742, on adult cardiomyocyte proliferation in mice [94]. It is likely that potential interaction of PPARδ with other transcriptional factors enables cardiomyocyte proliferation in the adult heart. Future investigations should focus on how PPARδ interacts with other transcription factors/signaling pathways to exert its biological functions. Further studies should also target to exploit PPARδ’s many potentially beneficial effects for the treatment of common cardiac disorders.

4. Upstream regulation of PPARδ

Several previous studies demonstrate that cardiac PPARδ is downregulated in various pathological states [34, 35, 99]. The mechanisms underlying the downregulation of cardiac PPARδ expression and activity is intriguing but remains elusive.

Nuclear receptor coactivator 6 (NCOA6) is a transcription coregulator. Mouse models of NCOA6 dysfunction develop severe dilated cardiomyopathy with impaired mitochondrial function and reduced activity of PPARδ [100]. It is not clear if the down-regulation of cardiac PPARδ is part of the pathological consequence or the co-regulator acts through an unknown mechanism that repressing the expression of PPARδ. An exact mechanism will require further investigations. PPARδ is modulated by epigenetic modification. Specific microRNAs repress the expression of cardiac PPARδ. For example, the hypoxia-inducible microRNA cluster miR-199a-214 represses approximately PPARδ target gene expression in the heart and impairs mitochondrial FAO [36, 70]. A recent study shows that the circadian repressors (crytochrome-1) CRY1 and CRY2 function as co-repressors for PPARδ, which represses a distinct subset of PPARδ target genes in skeletal muscle [101]. However, further study will be needed to determine if they exert similar PPARδ repression effect in the heart.

A recent study revealed that leptin administered via intracerebroventricular enhances cardiac FAO by activating PPARδ in the heart [102]. Various lipid species from the increased lipolysis by leptin down-stream signaling in the heart may serve as endogenous ligands that activate cardiac PPARδ by the central leptin. PPARδ can be deactivated by post-translational modification such as SUMOylation. Small ubiquitin-like modifier (SUMO)-specific proteases (SEPNs) that reverse protein modification by deSUMOylation of PPARδ and PPARγ to enhance FA metabolism in cultured C2C12 myotubes [103]. AMP-activated protein kinase (AMPK) is well-recognized cellular energy-sensing enzyme complex [104, 105]. PPARδ agonist GW501516 activates AMPK and stimulates glucose uptake in skeletal muscle [106, 107]. AMPK may interact with PPARδ to exert their gene regulation function with unknown mechanisms [108]. Given the well-established beneficial effects of AMPK activation in the heart (see review [109]) and similarity of skeletal muscle and heart muscle,
it is plausible that similar AMPK activation effects of PPARδ activation may also apply to the heart. However, it remains obscure how AMPK is activated by PPARδ, which presumably leads to increase energy metabolism. Further investigations are warranted. PPARδ can also be activated by an array of long-chain FAs and prostaglandins and other metabolites. However, the specificity and potency of these endogenous ligands appear to be relatively modest. Several selective PPARδ agonists have been developed and well documented, such as GW0742, GW501516, and L165041 [110–113]. Synthetic PPARδ antagonists, such as GSK-3787, are also available [114]. Several clinically used therapeutic compounds have been reported to be able to enhance the activity of PPARδ in addition to their specific therapeutic targets. Ramipril is an angiotensin-converting enzyme inhibitor, used to treat high blood pressure and congestive heart failure [115]. Interestingly, Ramipril can be normalized the decreased PPARδ and PPARγ mRNA in animals treated with the anti-cancer drug, daunorubicin [58]. The cholesterol-lowering drug, Atorvastatin, has also been reported to upregulate the expression of PPARδ in Angiotensin II-induced hypertrophic cardiomyocytes in vitro [34]. Another study showed that digoxin could upregulate cardiac PPARδ followed by improving lipid metabolism in the heart of diabetic rats [37]. Therefore, it appears that many currently used drugs may also exert PPARδ activation effects, in addition to those well-designed and characterized PPARδ-selective ligands. However, the underpinning mechanisms for their PPARδ activation effects need further investigations.

Besides the endogenous and synthetic PPARδ ligands, many naturally occurred compounds from plants have been shown to either act as PPARδ ligands or PPARδ enhancers. For example, green tea extract selectively activates PPARδ in cultured cardiomyocytes [116, 117]. A recent study demonstrates that physiological levels of caffeine enhance cell metabolism at least partially via PPARδ [118]. Although the in vivo effects of green tea and caffeine on the adult heart need further studies, the clinical implication in the tea and coffee drinking population is intriguing. Further study is required to determine if drinking tea or coffee may activate cardiac PPARδ and may exert beneficial effects as those we shown in transgenic mice with heightening cardiomyocyte-restricted PPARδ expression [40]. Baicalin is a natural flavone found in the extract of the rhizome of the perennial herb Scutellaria baicalensis, known as huangqin in China and is one of the most used herbs in Traditional Chinese Medicine for thousands of years [119]. Zhang et al. showed that baicalin restores cardiac PPARδ expression in vivo and in vitro in cultured cardiomyocytes [35]. Abscistic acid, a phytohormone, is among those newly identified PPARδ activators [120]. The cyclohexenyl chalcone panduratin A, isolated from Boesenbergia pandurata rhizomes, was shown to be a natural AMPK stimulator, with consequent activation of PPARα/δ [121]. Therapeutic potential of panduratin A, an LKB1-dependent AMP-activated protein kinase stimulator, is shown to activate PPARα/δ and can be an effective anti-obesity treatment [121]. Vaticanol C is reported to be a complex resveratrol tetramer activates PPARα and PPARδ, but not PPARγ both in vitro and in vivo [122]. Ginsenoside Rh2 treatment in type1-like diabetic rats can enhance cardiac expression of PPARδ and repress cardiac fibrosis [123]. The list of new identified natural activators of PPAR is still expanding. However, it remains unclear how we may use these potential natural PPARδ activators for prevention and alternative treatments of cardiac disorders. These studies do not provide potential mechanisms underlying the upregulation of cardiac PPARδ. At present, studies are still
absent to further determine which of the two PPAR subtypes (α and δ) exert the cardiac protective effects of these compounds. In systemic treatment, the cardiac PPARδ activators could have been due to their effects on other systems, eg., PPARδ exerts antihypertensive effects [124]. While the potential anti-hypertensive effect of activating PPARδ post additional beneficial effect when treating heart failure patients with hypertension, other systemic effects of PPARδ remain major confounding factors preventing the potential application. Therefore, it appears that the understanding of the molecular mechanisms for the specific changes in cardiac expression and activation of PPARδ are surprisingly scarce. Further investigations in the regulation of cardiac PPARδ may yield crucial insights into translatable therapies for treating heart disease.

5. Future Perspectives and Conclusion

As ligand-activated transcription factors, the PPARs represent an attractive target for the development of therapeutic agents. Synthetic PPARδ agonists such as GW0742, GW501516, and L165041 [110–113] have been developed and even went on to early clinical trials. Although controversial, the main concern remains to be its potential tumorigenesis effects (see review [125]). The systemic use of PPARδ is undoubtedly problematic because its seemingly differential effects on different cell types and tissues, which is evident by numerous studies using global and tissue-specific PPARδ transgenic and gene-targeting mice [30, 41, 69, 126–128]. On-going efforts on designed-synthesized tissue-specific PPARδ-selective ligands [129, 130] may give hope for targeting cardiac PPARδ for the treatment of metabolic derangement and mitochondrial dysfunction in cardiac pathological states.

Despite the identification of numerous natural ligands for PPARs, a major challenge is the lack of in-depth studies on most of them. New approaches have been proposed using the cellular and biophysical pipeline for the screening of PPARδ-selective ligands to avoid false positives [131]. Another alternative approach aims at further characterizing PPARδ targets to delineate relevant downstream regulatory pathways to avoid the unwanted effects.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81500312 and 81570366 to Q. L.), American Diabetes Association (1–17-IBS-184 to Q.Y.), NIH (R01HL13533 and R03AG055899 to Q.Y.).

References

[1]. Schoonjans K, Martin G, Staels B, and Auwerx J, “Peroxisome proliferator-activated receptors, orphans with ligands and functions,” Current Opinion in Lipidology, vol. 8, no. 3, pp. 159–166, 1997. [PubMed: 9211064]

[2]. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, and Rodan GA, “Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids,” Molecular Endocrinology, vol. 6, no. 10, pp. 1634–1641, 1992. [PubMed: 1333051]

[3]. Krey G, Keller H, Mahfoudi A et al., “Xenopus peroxisome proliferator activated receptors: Genomic organization, response element recognition, heterodimer formation with retinoid X

NucRceptor Res. Author manuscript; available in PMC 2019 April 24.
receptor and activation by fatty acids,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 47, no. 1–6, pp. 65–73, 1993. [PubMed: 8274443]
[4]. Oliver WR Jr., Shenk JL, Snaith MRet al., “A selective peroxisome proliferator-activated receptor agonist δ promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001.
[5]. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, and Muscat GEO, “The peroxisome proliferator-activated receptor β/δ agonist GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells,” Molecular Endocrinology, vol. 17, no. 12, pp. 2477–2493, 2003. [PubMed: 14525954]
[6]. Iwaisako K, Haimerl M, Paik Y-H et al., “Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 21, pp. E1369–E1376, 2012.
[7]. Jones D, Boudes PF, Swain MG et al., “Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study,” The Lancet Gastroenterology and Hepatology, vol. 2, no. 10, pp. 716–726, 2017. [PubMed: 28818518]
[8]. Kelly DP, “PPARs of the heart: Three is a crowd,” Circulation Research, vol. 92, no. 5, pp. 482–484, 2003. [PubMed: 12649261]
[9]. Ding Y, Yang KD, and Yang Q, “The role of, pp. ardelta-ardeltsignaling in the cardiovascular system. Prog Mol Biol Transl Sci,” in The role of, pp. 121–451, 121, 451–473, 2014.
[10]. Kim T, “Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system,” World Journal of Cardiology, vol. 5, no. 6, pp. 164, 2013. [PubMed: 23802046]
[11]. Han L, Shen W-J, Bittner S, Kraemer FB, and Azhar S, “PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ,” Future Cardiology, vol. 13, no. 3, pp. 279–296, 2017. [PubMed: 28581362]
[12]. Djouadi F, Brandt J, Weinheimer C, Leone T, Gonzalez F, and Kelly D, “The role of the peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac lipid metabolism,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 60, no. 5–6, pp. 339–343, 1999.
[13]. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, and Kelly DP, “Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1723–1730, 2000. [PubMed: 10862787]
[14]. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, and Mortensen RM, “Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice,” Circulation Research, vol. 97, no. 4, pp. 372–379, 2005. [PubMed: 16051889]
[15]. Ding G, Fu M, Qin Q et al., “Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage,” Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007. [PubMed: 17678635]
[16]. Luo J, Wu S, Liu J et al., “Conditional PPARγ knockout from cardiomyocytes of adult mice impairs myocardial fatty acid utilization and cardiac function,” American Journal of Translational Research, vol. 3, no. 1, pp. 61–72, 2010. [PubMed: 21139806]
[17]. Son N-H, Yu S, Tuinei J et al., “PPARγ-induced cardioliopotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation,” The Journal of Clinical Investigation, vol. 120, no. 10, pp. 3443–3454, 2010. [PubMed: 20852389]
[18]. Gilde AJ, van der Lee KA, and Willemens PH, “Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism,” Circulation Research, vol. 92, no. 5, pp. 518–524, 2003. [PubMed: 12600885]
[19]. Cheng L, Ding G, Qin Q et al., “Peroxisome proliferator-activated receptor δ activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes,” Biochemical and Biophysical Research Communications, vol. 313, no. 2, pp. 277–286, 2004. [PubMed: 14684157]
[20]. Barak Y, Liao D, He W et al., “Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol.99, no. 1, pp. 303–308, 2002.

[21]. Kliewer SA, Forman BM, Blumberg B et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994.

[22]. Braissant O, Foufelle F, Scotto C, Daucu M, and Wahl W, “Differential expression of peroxisome proliferator-activated receptors (PPARs); tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. [PubMed: 8536636]

[23]. Angione AR, Jiang C, Pan D, Wang Y-X, and Kuang S, “PPARδ regulates satellite cell proliferation and skeletal muscle regeneration,” Skeletal Muscle, vol. 1, no. 1, 2011.

[24]. Beyaz S, Mana MD, Roper J et al., “High-fat diet enhances stemness and tumorigenicity of intestinal progenitors,” Nature, vol. 531, no. 7592, pp. 53–58, 2016. [PubMed: 26935695]

[25]. Degenhardt T, Saramäki A, Malinen M et al., “Three Members of the Human Pyruvate Dehydrogenase Kinase Gene Family Are Direct Targets of the Peroxisome Proliferator-activated Receptor β/δ,” Journal of Molecular Biology, vol. 372, no. 2, pp. 341–355, 2007. [PubMed: 17669420]

[26]. Fan W, Waizenegger W, Lin CS et al., “PPARδ Promotes Running Endurance by Preserving Glucose,” Cell Metabolism, vol. 25, no. 5, pp. 1186–1193.e4, 2017. [PubMed: 28467934]

[27]. Ito K, Carracedo A, Weiss D et al., “A PML-PPAR- pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance,” Nature Medicine, vol. 18, no. 69, pp. 1350–1358, 2012.

[28]. Kocalis HE, Turney MK, Printz RL et al., “Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARδ) in mice leads to increased susceptibility to diet-induced obesity,” PLoS ONE, vol. 7, no. 8, 2012.

[29]. Kang K, Reilly SM, Karabacak V et al., “Adipocyte-derived Th2 cytokines and myeloid PPARd regulate macrophage polarization and insulin sensitivity,” Cell Metabolism, vol. 7, no. 6, pp. 485–495, 2008. [PubMed: 18522830]

[30]. Cheng L, Ding G, Qin Q et al., “Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy,” Nature Medicine, vol. 10, no. 11, pp. 1245–1250, 2004.

[31]. Stanley WC, Recchia FA, and Lopaschuk GD, “Myocardial substrate metabolism in the normal and failing heart,” Physiological Reviews, vol. 85, no. 3, pp. 1093–1129, 2005. [PubMed: 15987803]

[32]. Lionetti V, Stanley WC, and Recchia FA, “Modulating fatty acid oxidation in heart failure,” Cardiovascular Research, vol. 90, no. 2, pp. 202–209, 2011. [PubMed: 21289012]

[33]. Vázquez-Carrera M, “Unraveling the effects of PPARβ/δ on insulin resistance and cardiovascular disease,” Trends in Endocrinology & Metabolism, vol. 27, no. 5, pp. 319–334, 2016. [PubMed: 27005447]

[34]. Sheng L, Yang X, Ye P, Liu Y-X, and Han C-G, “Effect of Atorvastatin on Expression of Peroxisome Proliferator-activated Receptor Beta/delta in Angiotensin II-induced Hypertrophic Myocardial Cells in Vitro,” Chinese Medical Sciences Journal, vol. 30, no. 4, pp. 245–251, 2015. [PubMed: 26960306]

[35]. Zhang Y, Liao P, Zhu M et al., “Baicalin Attenuates Cardiac Dysfunction and Myocardial Remodeling in a Chronic Pressure-Overload Mice Model,” Cellular Physiology and Biochemistry, vol. 41, no. 3, pp. 849–864, 2017. [PubMed: 28214892]

[36]. El Azzouzi H, Leptidis S, Dirkx E et al., “The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation,” Cell Metabolism, vol. 18, no. 3, pp. 341–354, 2013. [PubMed: 24011070]

[37]. Sharon E et al., “Increase of Peroxisome Proliferator-activated Receptor δ (PPARδ) by Digoxin to Improve Lipid Metabolism in the Heart of Diabetic Rats,” Hormone and Metabolic Research, vol.45, no. 05, pp. 364–371, 2013. [PubMed: 23225238]

[38]. Lee S, Go G, Yoo M et al., “Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) activates promyogenic signaling pathways, thereby promoting myoblast differentiation,” Biochemical and...
Biophysical Research Communications, vol. 470, no. 1, pp. 157–162, 2016. [PubMed: 26768366]

[39]. Kapoor A, Collino M, Castiglia S, Fantozzi R, and Thiemermann C, “Activation of peroxisome proliferator-activated receptor-β/δ attenuates myocardial ischemia/reperfusion injury in the rat,” Shock, vol. 34, no. 2, pp. 117–124, 2010. [PubMed: 19997057]

[40]. Wang P, Liu J, Li Y et al., “Peroxisome proliferator-activated receptor δ is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart,” Circulation Research, vol. 106, no. 5, pp. 911–919, 2010. [PubMed: 20075336]

[41]. Liu J, Wang P, Luo J et al., “Peroxisome proliferator-activated receptor δ is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart,” Circulation Research, vol. 106, no. 5, pp. 911–919, 2010. [PubMed: 20075336]

[42]. Planavila A, Rodríguez-Calvo R, Jové M et al., “Peroxisome proliferator-activated receptor δ activation inhibits hypertrophy in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 65, no. 4, pp. 832–841, 2005. [PubMed: 15721863]

[43]. Pellieux C, Montessuit C, Papageorgiou I, and Lerch R, “Inactivation of peroxisome proliferator-activated receptor isoforms α, β/δ, and γ mediate distinct facets of hypertrophic transformation of adult cardiac myocytes,” Pflügers Archiv - European Journal of Physiology, vol. 455, no. 3, pp. 443–454, 2007. [PubMed: 17643263]

[44]. Kojonazarov B, Luitel H, Sydykov A et al., “The peroxisome proliferator–activated receptor δ agonist GW0742 has direct protective effects on right heart hypertrophy,” Pulmonary Circulation, vol. 3, no. 4, pp. 926–935, 2013. [PubMed: 25006409]

[45]. Randriamboavonjy JI, Loirand G, Vaillant N et al., “Cardiac protective effects of moringa oleifera seeds in spontaneous hypertensive rats,” American Journal of Hypertension, vol. 29, no. 7, pp. 873–881, 2016. [PubMed: 26864583]

[46]. Burkart EM, Sambandam N, Han X et al., “Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. [PubMed: 18037994]

[47]. Magadum A, Ding Y, He L et al., “Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repair,” Cell Research, vol. 27, no. 8, pp. 1002–1019, 2017. [PubMed: 28621328]

[48]. Park JR, Ahn JH, Jung MH et al., “Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction,” PLoS ONE, vol. 11, no. 2, p. e0148510, 2016. [PubMed: 26862756]

[49]. Altiери P, Spallarossa P, Barisione C et al., “Inhibition of Doxorubicin-Induced Senescence by PPARδ Activation Agonists in Cardiac Muscle Cells: Cooperation between PPARδ and Bcl6,” PLoS ONE, vol. 7, no. 9, 2012.

[50]. Chen Zhih-Cherng, Chen Li-Jen, and Cheng Juei-Tang, “Doxorubicin-Induced Cardiac Toxicity Is Mediated by Lowering of Peroxisome Proliferator-Activated Receptor δ Expression in Rats,” PPAR Research, vol. 2013, Article ID 456042, 8 pages, 2013.

[51]. Chang W-T, Li J, Haung H-H et al., “Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation,” Journal of Cellular Biochemistry, vol. 112, no. 10, pp. 2873–2881, 2011. [PubMed: 21618589]

[52]. Bayeva M, Sawicki KT, and Ardehali H, “Taking diabetes to heart—deregulation of myocardial lipid metabolism in diabetic cardiomyopathy,” Journal of the American Heart Association, vol. 2, no. 6, Article ID e000433, 2013.

[53]. Bouzina S and Abel ED, “Diabetic cardiomyopathy revisited,” Circulation, vol. 115, no. 25, pp. 3213–3223, 2007. [PubMed: 17592090]

[54]. Schilling JD, “The Mitochondria in Diabetic Heart Failure: From Pathogenesis to Therapeutic Promise,” Antioxidants & Redox Signaling, vol. 22, no. 17, pp. 1515–1526, 2015. [PubMed: 25761843]

[55]. Georgiadi A, Lichtenstein L, Degenhardt T et al., “Induction of cardiac angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor βδ and protects against fatty acid-induced oxidative stress,” Circulation Research, vol. 106, no. 11, pp. 1712–1721, 2010. [PubMed: 20378851]
[56]. Lee T-I, Kao Y-H, Tsai W-C, Chung C-C, Chen Y-C, and Chen Y-J, “HDAC inhibition modulates cardiac PPARs and fatty acid metabolism in diabetic cardiomyopathy,” PPAR Research, vol. 2016, 2016.

[57]. Tsai Cheng-Chia, Chan Paul, Chen Li-Jen, Chen Kuei Chang Zhongmin Liu, and Lin Jia-Wei, “Merit of Ginseng in the Treatment of Heart Failure in Type 1-Like Diabetic Rats,” BioMed Research International, vol. 2014, Article ID 484161, 8 pages, 2014.

[58]. Cernecka H, Doka G, Sranksova J et al., “Ramipril restores PPARβ/δ and PPARγ expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat,” European Journal of Pharmacology, vol. 791, pp. 244–253, 2016. [PubMed: 27592051]

[59]. Finck BN, Lehman JJ, Leone TC et al., “The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus,” The Journal of Clinical Investigation, vol. 109, no. 1, pp. 121–130, 2002. [PubMed: 11781357]

[60]. Young ME, Laws FA, Goodwin GW, and Taegtmeyer H, “Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart,” The Journal of Biological Chemistry, vol. 276, no. 48, pp. 44390–44395, 2001. [PubMed: 11574533]

[61]. Zou J, Le K, Xu S et al., “Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-alpha partly via preventing p65-NFkappaB binding to NFATc4,” Molecular and Cellular Endocrinology, vol. 370, no. 1–2, pp. 103–112, 2013. [PubMed: 23518069]

[62]. Lam VH, Zhang L, Huqi A et al., “Activating PPARα Prevents Post-Ischemic Contractile Dysfunction in Hypertrophied Neonatal Hearts,” Circulation Research, vol. 117, no. 1, pp. 41–51, 2015. [PubMed: 25977309]

[63]. Xu Si-Chi, Ma Zhen-Guo, Wei Wen-Ying, Yuan Yu-Pei, and Tang Qi-Zhu, “Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis,” PPAR Research, vol. 2017, Article ID 5789714, 12 pages, 2017.

[64]. Rana S, Datta R, Chaudhuri RD, Chatterjee E, Chawla-Sarkar M, and Sarkar S, “Nonotized PPARα overexpression targeted to hypertrophied myocardium improves cardiac function by attenuating the p53-GSK3β mediated mitochondrial death pathway,” Antioxidants & Redox Signaling, 2018.

[65]. Palomer X, Barroso E, Zarei M, Botteri G, Vazquez-Carrera M, and pp., “arbeta-arbetdelta and lipid metabolism in the heart,” Biochimica et Biophysica Acta, pp. 1861–1569, 2016. [PubMed: 27425035]

[66]. Lee Wang-Soo and Kim Jaetaek, “Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions,” PPAR Research, vol. 2015, Article ID 271983, 18 pages, 2015.

[67]. Yang Q and Cheng L, “Molecular regulation of lipotoxicity in the heart,” Drug Discovery Today: Disease Mechanisms, vol. 2, no. 1, pp. 101–107, 2005.

[68]. Yang Q and Li Y, “Roles of PPARs on regulating myocardial energy and lipid homeostasis,” Journal of Molecular Medicine, vol. 85, no. 7, pp. 697–706, 2007. [PubMed: 17356846]

[69]. Liu Jian, Wang Peiyong, He Lan et al., “Cardiomyocyte-Restricted Deletion of PPARβ/δ in PPARα-Null Mice Causes Impaired Mitochondrial Biogenesis and Defense, but No Further Depression of Myocardial Fatty Acid Oxidation,” PPAR Research, vol. 2011, Article ID 372854, 13 pages, 2011.

[70]. Kuo S, Ku P, Chen L, Niu H, and Cheng J, “Activation of Receptors δ (PPARδ) by Agonist (GW0742) may Enhance Lipid Metabolism in Heart both In Vivo and In Vitro,” Hormone and Metabolic Research, vol. 45, no. 12, pp. 880–886, 2013. [PubMed: 23803968]

[71]. Watanabe K, Fujii H, Takahashi T et al., “Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity,” The Journal of Biological Chemistry, vol. 275, no. 29, pp. 22293–22299, 2000. [PubMed: 10801788]

[72]. Barlaka E, Görbe A, Gáspár R, Pálóczi J, Ferdinandy P, and Lazou A, “Activation of PPARβ/δ protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of
reactive oxygen/nitrogen species and expression of matrix metalloproteinases,” Pharmacological Research, vol. 95-96, pp. 102–110, 2015. [PubMed: 25828396]

[73]. Yue TL, Nerurkar SS, Bao W et al., “In vivo activation of peroxisome proliferator-activated receptor- δ protects the heart from ischemia/reperfusion injury in Zucker fatty rats,” The Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 466–474, 2008. [PubMed: 18287212]

[74]. Mehta JL, Nichols WW, and Mehta P. “Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion,” Journal of the American College of Cardiology, vol. 11, no. 6, pp. 1309–1316, 1988. [PubMed: 3284944]

[75]. Frangogiannis NG, “The inflammatory response in myocardial injury, repair, and remodelling,” Nature Reviews Cardiology, vol. 11, no. 5, pp. 255–265, 2014. [PubMed: 24663091]

[76]. Smeets PJH, Teunissen BEJ, Planavila A et al., “Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARα and PPAR δ,” The Journal of Biological Chemistry, vol. 283, no. 43, pp. 29109–29118, 2008. [PubMed: 18701451]

[77]. Cohen AB, Stevens MD, Miller EJ et al., “Neutrophil-activating peptide-2 in patients with pulmonary edema from congestive heart failure or ARDS,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 264, no. 5, pp. L490–L495, 1993.

[78]. Heymans S, Hirsch E, Anker SD et al., “Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology,” European Journal of Heart Failure, vol. 11, no. 2, pp. 119–129, 2009. [PubMed: 19168509]

[79]. Suthahar N, Meijers WC, Silljé HHW, and de Boer RA, “From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities,” Current Heart Failure Reports, vol. 14, no. 4, pp. 235–250, 2017. [PubMed: 28707261]

[80]. Jackson SM, Parhami F, Xi X-P et al., “Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2094–2104, 1999.

[81]. Su CG, Wen X, Bailey ST et al., “A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response,” The Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999. [PubMed: 10449430]

[82]. Fruchart J-C, Duriez P, and Staels B, “Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis,” Current Opinion in Lipidology, vol. 10, no. 3, pp. 245–257, 1999. [PubMed: 10431661]

[83]. Tan NS, Michalik L, Noy N et al., “Critical roles of PPARbeta/delta in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 24, pp. 3263–3277, 2001. [PubMed: 11751632]

[84]. Li AC, Binder CJ, Gutierrez A et al., “Differential inclusion of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ,” The Journal of Clinical Investigation, vol. 114, no. 11, pp. 1564–1576, 2004. [PubMed: 15578089]

[85]. Liang Y, Lin S, Beyer TP et al., “A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes,” Journal of Neurochemistry, vol. 88, no. 3, pp. 623–634, 2004. [PubMed: 14720212]

[86]. Álvarez-Guardia D, Palomer X, Coll T et al., “PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells,” Biochimica et Biophysica Acta, vol. 1811, no. 2, pp. 59–67, 2011. [PubMed: 21070867]

[87]. Ding G, Cheng L, Qin Q, Frontin S, and Yang Q. “PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 40, no. 6, pp. 821–828, 2006. [PubMed: 16698033]

[88]. Lee C, Chawla A, Urbiztondo N, Liao D, Boisvert WA, and Evans RM, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. [PubMed: 12970571]
[89]. Fan Y, Wang Y, Tang Z et al., “Suppression of pro-inflammatory adhesion molecules by PPAR-δ in human vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 315–321, 2008.

[90]. Takata Y, Liu J, Yin F et al., “PPAR-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 105, no. 11, pp. 4277–4282, 2008.

[91]. Palomer X, Capdevila-Busquets E, Botteri G et al., “PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells,” International Journal of Cardiology, vol. 174, no. 1, pp. 110–118, 2014. [PubMed: 24767130]

[92]. Samokhvalov V, Zlobine I, Jamieson KL et al., “PPARβ signaling mediates the cytotoxicity of DHA in H9c2 cells,” Toxicology Letters, vol. 232, no. 1, pp. 10–20, 2015. [PubMed: 25300478]

[93]. Wagner N, Jehl-Piétri C, Lopez P et al., “Peroxisome proliferator-activated receptor β stimulation induces rapid cardiac growth and angiogenesis via direct activation of calceinurin,” Cardiovascular Research, vol. 83, no. 1, pp. 61–71, 2009. [PubMed: 19351742]

[94]. Ajith TA and Jayakumar TG, “Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease,” Clinical and Experimental Pharmacology and Physiology, vol. 43, no. 7, pp. 649–658, 2016. [PubMed: 27115677]

[95]. Wagner K-D, Vukolic A, Baudouy D, Michiels J-F, and Wagner N. “Inducible conditional vascular-specific overexpression of peroxisome proliferator-activated receptor beta/delta leads to rapid cardiac hypertrophy,” PPAR Research, vol. 2016, 2016.

[96]. Akhmedov AT and Marín-García J, “Myocardial regeneration of the failing heart,” Heart Failure Reviews, vol. 18, no. 6, pp. 815–833, 2013. [PubMed: 23001638]

[97]. Yutzey KE, “Cardiomyocyte proliferation,” Circulation Research, vol. 120, no. 4, pp. 627–629, 2017. [PubMed: 28209795]

[98]. Yuan X and Braun T, “Multimodal Regulation of Cardiac Myocyte Proliferation,” Circulation Research, vol. 121, no. 3, pp. 293–309, 2017. [PubMed: 28729454]

[99]. Chen Z, Lee KS, Chen L et al., “Cardiac Peroxisome Proliferator-Activated Receptor δ (PPARδ) as a New Target for Increased Contractility without Altering Heart Rate,” PLoS ONE, vol. 8, no. 5, e64229, 2013. [PubMed: 23724037]

[100]. Roh J-I, Cheong C, Sung Y et al., “Perturbation of NCOA6 leads to dilated cardiomyopathy,” Cell Reports, vol. 8, no. 4, pp. 991–998, 2014. [PubMed: 25131203]

[101]. Jordan SD, Kriebs A, Vaughan M et al., “CRY1/2 Selectively Repress PPARδ and Limit Exercise Capacity,” Cell Metabolism, vol. 26, no. 1, pp. 243–255.e6, 2017. [PubMed: 28683290]

[102]. Mora C, Pintado C, Rubio B et al., “Central leptin regulates heart lipid content by selectively increasing PPAR β/δ expression,” Journal of Endocrinology, vol. 236, no. 1, pp. 43–56, 2018. [PubMed: 29109080]

[103]. Koo YD, Choi JW, Kim M et al., “SUMO-Specific Protease 2 (SENP2) is an important regulator of fatty acid metabolism in skeletal muscle,” Diabetes, vol. 64, no. 7, pp. 2420–2431, 2015. [PubMed: 25784542]

[104]. Beg ZH, Allmann DW, and Gibson DM, “Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol,” Biochemical and Biophysical Research Communications, vol. 54, no. 4, pp. 1362–1369, 1973. [PubMed: 4356818]

[105]. Garcia D and Shaw RJ, “AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance,” Molecular Cell, vol. 66, no. 6, pp. 789–800, 2017. [PubMed: 28622524]

[106]. Gan Z, Burkart-Hartman EM, Han D-H et al., “The nuclear receptor PPARβ/δ programs muscle glucose metabolism in cooperation with AMPK and MEF2,” Genes & Development, vol. 25, no. 24, pp. 2619–2630, 2011. [PubMed: 22135324]

[107]. Salvadó L, Barroso E, Gómez-Foix AM et al., “PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism,” Diabetologia, vol. 57, no. 10, pp. 2126–2135, 2014. [PubMed: 25063273]
[108]. Kemmerer M, Finkernagel F, Cavalcante MF et al., “AMP-activated protein kinase interacts with the peroxisome proliferator-activated receptor delta to induce genes affecting fatty acid oxidation in human macrophages,” PLoS ONE, vol. 10, no. 6, Article ID e0130893, 2015.

[109]. Kim TT and Dyck JR, “Is AMPK the savior of the failing heart?” Trends in Endocrinology & Metabolism, vol. 26, no. 1, pp. 40–48, 2015. [PubMed: 25439672]

[110]. Berger J, Leibowitz MD, Doebber TW et al., “Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects,” The Journal of Biological Chemistry, vol. 274, no. 10, pp. 6718–6725, 1999. [PubMed: 10037770]

[111]. Leibowitz MD, Fiévet C, Hennuyer N et al., “Activation of PPARδ alters lipid metabolism in db/db mice,” FEBS Letters, vol. 473, no. 3, pp. 333–336, 2000. [PubMed: 10818235]

[112]. Wolf G, “The Function of the Nuclear Receptor Peroxisome Proliferator-activated Receptor Delta in Energy Homeostasis,” Nutrition Reviews, vol. 61, no. 11, pp. 387–390, 2003. [PubMed: 14677574]

[113]. Sznaidman ML, Haffner CD, Maloney PR et al., “Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) – Synthesis and biological activity,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003. [PubMed: 12699745]

[114]. Shearer BG, Wiethe RW, Ashe A et al., “Identification and characterization of 4-chloro-N-(2-[5-trifluoromethyl)-2-pyridyl] sulfonyl ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist,” Journal of Medicinal Chemistry, vol. 53, no. 4, pp. 1857–1861, 2010. [PubMed: 20128594]

[115]. Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, and Tu JV, “Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure,” Canadian Medical Association Journal, vol. 178, no. 10, pp. 1303–1311, 2008. [PubMed: 18458262]

[116]. Danesi F, di Nunzio M, Boschetti E, and Bordoni A, “Green tea extract selectively activates peroxisome proliferator-activated receptor beta/delta in cultured cardiomyocytes,” British Journal of Nutrition, vol. 101, no. 12, pp. 1736–1739, 2009. [PubMed: 19055854]

[117]. Hrelia S, Bordoni A, Angeloni C et al., “Green tea extracts can counteract the modification of fatty acid composition induced by doxorubicin in cultured cardiomyocytes,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 66, no. 5–6, pp. 519–524, 2002.

[118]. Schnuck JK, Gould LM, Parry HA et al., “Metabolic effects of physiological levels of caffeine in myotubes,” Journal of Physiology and Biochemistry, vol. 74, no. 1, pp. 35–45, 2018. [PubMed: 29198059]

[119]. Zhu Y, [the study on baicalin in china]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 13, 567–569, 1993.

[120]. Mollashahi M, Abbasnejad M, and Esmaeili-Mahani S, “Phytohormone abscisic acid elicits antinociceptive effects in rats through the activation of opioid and peroxisome proliferator-activated receptors β/δ,” European Journal of Pharmacology, vol. 832, pp. 75–80, 2018. [PubMed: 29778745]

[121]. Kim D, Lee M, Jo K, Lee K, and Hwang J, “Therapeutic potential of panduratin A, LKB1-dependent AMP-activated protein kinase stimulator, with activation of PPARα/δ for the treatment of obesity,” Diabetes, Obesity and Metabolism, vol. 13, no. 7, pp. 584–593, 2011.

[122]. Tsukamoto T, Nakata R, Tamura E et al., “Vaticanol C, a resveratrol tetramer, activates PPARα and PPARβ/δ in vitro and in vivo,” Nutrition & Metabolism, vol. 7, no. 1, p. 46, 2010. [PubMed: 20504373]

[123]. Lo S, Hsu C, Niu H, Niu C, Cheng J, and Chen Z, “Ginsenoside Rh2 Improves Cardiac Fibrosis via PPARδ – STAT3 Signaling in Type 1-Like Diabetic Rats,” International Journal of Molecular Sciences, vol. 18, no. 7, p. 1364, 2017.

[124]. Toral M, Romero M, Pérez-Vizcaíno F, Duarte J, and Jiménez R, “Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 312, no. 2, pp. H189–H200, 2017. [PubMed: 27881385]

[125]. Muller R and pp. arbeta-arbetdelta in, “human cancer,” Biochimie, pp. 136–90, 2017.
[126]. Wang Y-X, Lee C-H, Tiep S et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. [PubMed: 12705865]

[127]. d’Uscio LV, He T, Santhanam AVR, Tai L-J, Evans RM, and Katusic ZS, “Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-delta gene,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 306, no. 7, pp. H1001–H1010, 2014. [PubMed: 24486511]

[128]. Zuo X, Peng Z, Moussalli MJ et al., “Targeted genetic disruption of peroxisome proliferator-activated receptor-δ and colonic tumorigenesis,” Journal of the National Cancer Institute, vol. 101, no. 10, pp. 762–767, 2009. [PubMed: 19436036]

[129]. Bugge A and Holst D, “PPAR agonists, - Could tissue targeting pave the way?” Biochimie, vol. 136, pp. 100–104, 2017. [PubMed: 27916640]

[130]. Maltarollo VG, Kronenberger T, Windshugel B, Wrenger C, Trossini GH, and Honorio KM, “Advances and Challenges in Drug Design of PPARδ Ligands,” Current Drug Targets, vol. 19, no. 2, pp. 144–154, 2018. [PubMed: 28413978]

[131]. Videira Natália Bernardi, Batista Fernanda Aparecida Heleno, Cordeiro Artur Torres, and Figueira Ana Carolina Migliorini, “Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives,” PPAR Research, vol. 2018, Article ID 3681590, 14 pages, 2018.
**Figure 1: PPARδ plays a crucial role in cardiac pathophysiology:**

PPARδ signaling is impaired in the heart under various pathological conditions, such as pathological cardiac hypertrophy, myocardial ischemia/reperfusion, doxorubicin cardiotoxicity and diabetic cardiomyopathy. PPARδ deficiency in the heart leads to cardiac dysfunction, myocardial lipid accumulation, cardiac hypertrophy/remodeling and heart failure.
Figure 2: The pleiotropic and integrated effects of PPARδ that affects cardiac structure and function.
Investigations in the past 15 years uncovered the potential mechanisms underlying the beneficial roles of cardiac PPARδ in determining cardiac pathophysiology. In addition to direct transcription regulation of mitochondrial biogenesis, substrate utilization and antioxidant defense in the heart, PPARδ exerts anti-inflammation and cardiomyocyte proliferated effects probably via interacting with other transcription factors and cellular signaling pathways.
Figure 3: Upstream regulation of PPARδ in the heart.
The cardiac expression and activity of PPARδ can be elevated by various PPARδ agonists (endogenous, synthetic and natural ligands), post-translational modification (deSUMOylation), leptin and AMPK (AMP-activated protein kinase). In contrast, PPARδ antagonists, microRNA (miR-199a-214) and nuclear receptor coregulator (Nuclear receptor coactivator 6). Arrows with solid lines: activation; Arrows with dash lines: inhibition.